July 2022 Content Release Copied
Problems
This release contains additional TNM values, and Staging selections for Breast Cancer to treat the new HER- 2/Neu Status, Low’ status as Negative within the staging calculator until it is addressed by AJCC.
The new content does not affect previous charting documented on existing patients. All previous charting is brought forward during a subsequent visit, just as it did prior to this release.
Additions
The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.
Breast Cancer HER-2/Neu status now contains “Low” inserted after positive and prior to negative. To provide clarity, definitions are present for each of the existing and new selections.
- Positive: IHC 3+ or IHC 2+/ISH-positive
- Low: IHC 1+ or IHC 2+/ISH-negative
- Negative: IHC 0
- Unknown
BRAF Mutation is now available for documentation for Fallopian Tube Cancer and Ovarian and Primary Peritoneal Cancer with the following options:
- BRAF V600E (Mutated)
- Wild-type
- Mutations
- Unknown
Myelofibrosis has been updated to include new risk categories:
MIPSS-70 Risk Category
- Low (0 – 1 point)
- Intermediate-1 (2 – 3 points)
- Intermediate-2 (4 points)
- High (5 or greater points)
MIPSS-70+ v2.0 Risk Category
- Very Low (0 points)
- Low (1 – 2 points)
- Intermediate-1 (3 points)
- Intermediate-2 (4 points)
- High (5 – 8 points)
- Very High (9 or greater points)
MYSEC-PM Risk Category
- Low (Less than 11 points)
- Intermediate-1 (11 – 13 points)
- Intermediate-2 (14 – 15 points)
- High (16 or greater points)
- Unknown
Removals
Myelofibrosis no longer contains documentation for IPSS-Marrow Blasts (%), IPSS-Karyotype, IPSS-Cytopenia, and IPSS Score.
Charge Capture
The following items are available for documentation in Problems and appear on the Charge Capture Report (CCR). Additional ICD-10 codes may display to present the surrounding nodes.
| Problem | ICD-10 Codes |
| Administration of Respiratory Syncytial virus immune globulin, human (procedure) | Z29.11 Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV) |
| Epilepsy (disorder) | G40.001 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, with status epilepticus
G40.009 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status epilepticus G40.011 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus G40.019 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus G40.101 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status epilepticus G40.109 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus G40.111 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus G40.119 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus G40.201 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus G40.209 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus G40.211 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus G40.219 Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus G40.301 Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus G40.309 Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus G40.311 Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus G40.319 Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus G40.401 Other generalized epilepsy and epileptic syndromes, not intractable, with status epilepticus G40.409 Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus G40.411 Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus G40.419 Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus G40.501 Epileptic seizures related to external causes, not intractable, with status epilepticus G40.509 Epileptic seizures related to external causes, not intractable, without status epilepticus G40.801 Other epilepsy, not intractable, with status epilepticus G40.802 Other epilepsy, not intractable, without status epilepticus G40.804 Other epilepsy, intractable, without status epilepticus G40.811 Lennox-Gastaut syndrome, not intractable, with status epilepticus G40.812 Lennox-Gastaut syndrome, not intractable, without status epilepticus G40.814 Lennox-Gastaut syndrome, intractable, without status epilepticus G40.821 Epileptic spasms, not intractable, with status epilepticus G40.822 Epileptic spasms, not intractable, without status epilepticus G40.823 Epileptic spasms, intractable, with status epilepticus G40.834 Dravet syndrome, intractable, without status epilepticus G40.89 Other seizures G40.901 Epilepsy, unspecified, not intractable, with status epilepticus G40.909 Epilepsy, unspecified, not intractable, without status epilepticus G40.911 Epilepsy, unspecified, intractable, with status epilepticus G40.919 Epilepsy, unspecified, intractable, without status epilepticus G40.A09 Absence epileptic syndrome, not intractable, without status epilepticus ICD10CM G40.A19 Absence epileptic syndrome, intractable, without status epilepticus G40.B09 Juvenile myoclonic epilepsy, not intractable, without status epilepticus G40.B11 Juvenile myoclonic epilepsy, intractable, with status epilepticus G40.B19 Juvenile myoclonic epilepsy, intractable, without status epilepticus |
| Human immunodeficiency virus infection (disorder) | B20 Human immunodeficiency virus [HIV] disease |
| Peritonitis (disorder) | K65.0 Generalized (acute) peritonitis K65.1 Peritoneal abscess
K65.2 Spontaneous bacterial peritonitis K65.3 Choleperitonitis K65.4 Sclerosing mesenteritis K65.8 Other peritonitis K65.9 Peritonitis, unspecified |
| Sepsis (disorder) | A40.0 Sepsis due to streptococcus, group A A40.1Sepsis due to streptococcus, group B A40.3 Sepsis due to Streptococcus pneumoniae A40.8 Other streptococcal sepsis
A40.9 Streptococcal sepsis, unspecified A41.01 Sepsis due to Methicillin susceptible Staphylococcus aureus A41.02 Sepsis due to Methicillin resistant Staphylococcus aureus A41.1 Sepsis due to other specified staphylococcus A41.2 Sepsis due to unspecified staphylococcus A41.3 Sepsis due to Hemophilus influenzae A41.4 Sepsis due to anaerobes A41.50 Gram-negative sepsis, unspecified A41.51 Sepsis due to Escherichia coli [E. coli] A41.52 Sepsis due to Pseudomonas A41.53 Sepsis due to Serratia A41.59 Other Gram-negative sepsis A41.81 Sepsis due to Enterococcus A41.89 Other specified sepsis A41.9 Sepsis, unspecified organism A42.7 Actinomycotic sepsis R65.10 Systemic inflammatory response syndrome (SIRS) of non-infectious origin without acute organ dysfunction R65.11 Systemic inflammatory response syndrome (SIRS) of non-infectious origin with acute organ dysfunction R65.20 Severe sepsis without septic shock R65.21 Severe sepsis with septic shock T81.44XA Sepsis following a procedure, initial encounter T81.44XD Sepsis following a procedure, subsequent encounter T81.44XS Sepsis following a procedure, sequela |
| Vomiting (disorder) | R11.10 Vomiting unspecified R11.11 Vomiting without nausea R11.12 Projectile vomiting R11.13 Vomiting of fecal matter R11.14 Bilious vomiting
R11.15 Cyclical vomiting syndrome unrelated to migraine R11.2 Nausea with vomiting, unspecified |
Lab Analytes & Panels
Additions
- Cholesterol panel, pleural fluid
- Cholesterol, pleural fluid, mg/dL
- CMI666-Her2/Neu FISH panel
- ERBB2 (Her2/Neu)
- Histoplasmosis H band
- Histoplasmosis M band
- Invitae Atypical Hemolytic Uremic Syndrome
- and Thrombotic Microangiopathies panel
- Invitae Atypical Hemolytic Uremic Syndrome
- and Thrombotic Microangiopathies result
- Invitae Chronic Pancreatitis panel
- Invitae Chronic Pancreatitis result
- Invitae Familial Erythrocytosis panel
- Invitae Familial Erythrocytosis result
- Invitae Inborn Errors of Immunity and
- Cytopenias panel
- Invitae Inborn Errors of Immunity and
- Cytopenias result
- Invitae Monogenic diabetes panel
- Invitae Monogenic diabetes result
- MOG Ab CBA, serum
- MOG Ab w/ Reflex to titer panel
- Tempus genetics report
Medications
Additions
- Abelacimab invest IV
- Abelacimab invest Subcutaneous
- GM-CSF (part of GLSI-100) invest Intradermal
- PreviDent 5000 Dry Mouth 1.1 % dental paste
- GP2 (part of GLSI-100) invest Intradermal
- HPN424 invest Subcutaneous
- INCAGN02385 invest IV
- INCAGN02390 invest IV
- MRTX1719 invest Oral
- Placebo IV
- SPYK04 invest Oral W_pro1 invest IV
Updates
| Medication | Update |
| Cemiplimab invest (REGN2810 invest IV) | New dose Unit available:
|
| Nitroglycerin Sublingual | New default Form available:
|
| TT-00420 invest Oral | New Form(s) available:
|
Regimen Library
The Collaborative Care Committee recently voted to APPROVE the addition of Venous Thromboembolism (VTE) Prophylaxis into Multiple Myeloma regimens. To complete the initiative, the remaining updates to existing regimen templates within iKnowMed have been completed. For more information, please click here.
Additions
- Azacitidine D1-5,8-9 + Ivosidenib Q28D
- Darbepoetin alfa Q7D (Myelofibrosis)
- Epoetin alfa Q7D (Myelofibrosis)
- FOLFIRINOX (Modified) + Panitumumab Q14D
- Lenalidomide D1-21 +/- Prednisone Q28D
- Nivolumab D1,15 + Fluorouracil CIV D1-5 + Cisplatin Q28D
- Ruxolitinib + Decitabine D8-12 Q28D
- Ruxolitinib Q28D (3 cycles) fb Azacitidine D1-5 + Ruxolitinib Q28D
- Thalidomide +/- Prednisone Q28D
- Topotecan D1,8,15 + Bevacizumab BIOSIMILAR D1,15 Q28D
Updates
Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.
- Amyloidosis
- Multiple Myeloma (MM)
Renames
| Previous Name | New Name |
| Bendamustine D1,2 Q28D | Bendamustine D1,2 Q28D (MM) |
Research Regimens
Additions
To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.
Updates
| Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes | |
| USOR 18004 | X | |||
| USOR 18183 | X | X | X | Now available:
|
| USOR 18263 | X | |||
| USOR 18283 | X | X | ||
| USOR 19034 | Now available:
|
|||
| USOR 19082 | X | X | ||
| USOR 19182 | X | X | X | |
| USOR 19241 | X | X | ||
| USOR 20176 | X | Now available:
No longer available:
|
||
| USOR 20245 | X | X | Now available:
|
|
| USOR 20282 | X | X | ||
| USOR 20289 | X | |||
| USOR 20310 | X | X | X | |
| USOR 20382 | X | X | X | |
| USOR 20384 | X | X | ||
| USOR 20396 | X | X | ||
| USOR 21281 | X | X | ||
| USOR 21455 | X | X | X | |
| USOR 21456 | X | X | X | |
| USOR 21461 | X | X | ||
| USOR 21462 | X | X | X | |
| USOR 21468 | X | X | ||
| USOR 21536 | X | |||
| USOR 21537 | X |
Billing & HCPCS Codes
Updates
| Medication | HCPCS Code |
| COVID-19 Vaccine, mRNA, Pediatric (Moderna) (PF) IM (6 yrs thru 11 yrs) (Unapproved) | 91309 per
|
| Ranibizumab-nuna Intravitreal (Byooviz) | Q5124 per
|
| Risankizumab-rzaa IV (Skyrizi) | J3590 per
|